Simon Buczacki

Another PDOC position in my group to join an ongoing collaborative project between Sanger and BRIC. Funded by Open Targets.

my.corehr.com/pls/uoxrecru...

New CRUK Post-doc position in our group. #mutationalorder #multiomics #cancer.
my.corehr.com/pls/uoxrecru...

t.co/wF4ql4c3V8

We're humbled to have been awarded a CRUK Programme Foundation Award to further progress our work on mutational order in cancer. New post-doctoral positions in our group to be advertised shortly. @ndsurgicalsci.bsky.social @oxfordcancer.bsky.social

Fantastic end to a good week for the lab. Amazing grant news. Paper submitted. Gold LEAF accreditation.

Broad implications for path/surgical standards and CME

Each additional node however provides a survival benefit - an effect driven by tumour biology. Lymph node yield = prognostic marker rather than quality indicator.

Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer - British Journal of Cancer British Journal of Cancer - Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer

New paper. Why do we try to remove increasingly large numbers of lymph nodes in colon cancer surgery? Here we follow up our BJC 2022 paper with ~370K patients in England and USA. Only 9 LNs are required to stage the cancer.
www.nature.com/articles/s41...

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent ...

www.cancer.ox.ac.uk/news/oxford-...